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Abstract 
Carbohydrate‑Active enZYme (CAZY) GH89 family enzymes catalyze the cleavage of terminal α‑N‑acetylglucosamine 
from glycans and glycoconjugates. Although structurally and mechanistically similar to the human lysosomal α‑N‑
acetylglucosaminidase (hNAGLU) in GH89 which is involved in the degradation of heparan sulfate in the lysosome, 
the reported bacterial GH89 enzymes characterized so far have no or low activity toward α‑N‑acetylglucosamine‑
terminated heparosan oligosaccharides, the preferred substrates of hNAGLU. We cloned and expressed several soluble 
and active recombinant bacterial GH89 enzymes in Escherichia coli. Among these enzymes, a truncated recombinant 
α‑N‑acetylglucosaminidase from gut symbiotic bacterium Bacteroides thetaiotaomicron ∆22Bt3590 was found to cata‑
lyze the cleavage of the terminal α1–4‑linked N‑acetylglucosamine (GlcNAc) from a heparosan disaccharide with high 
efficiency. Heparosan oligosaccharides with lengths up to decasaccharide were also suitable substrates. This bacterial 
α‑N‑acetylglucosaminidase could be a useful catalyst for heparan sulfate analysis.
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Key points
• Active GH89 recombinant bacterial homologues of 
human lysosomal α-N-acetylglucosaminidase (hNA-
GLU) are obtained.
• N-terminal truncation improves the soluble expres-
sion of several bacterial α-N-acetylglucosaminidases 
in E. coli.
• ∆22Bt3590 is expressed in E. coli at a level of 
136 mg/L and is biochemically characterized.
• ∆22Bt3590 can catalyze the hydrolysis of heparosan 
oligosaccharides of different lengths.
Introduction
α-N-Acetylglucosaminidases (EC 3.2.1.50) are glyco-
side hydrolases (GH) that catalyze the cleavage of the 
terminal  N-acetylglucosamine from α-linked N-acetyl-
glucosaminides (GlcNAcαOR). They have been grouped 
in the Carbohydrate-Active enZYme (CAZY) database 
(www. cazy. org) (Henrissat 1991) GH89 family based 
on their protein sequence similarity. Among more 
than 1000 predicted GH89 family members (>  100 
from eukaryote and  >  900 from bacteria), only human 
α-N-acetylglucosaminidase (hNAGLU) (Weber et  al. 
1996) and its homologues from bacteria Clostridium 
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perfringens ATCC 13124 (Ficko-Blean et  al. 2008), 
Clostridium perfringens strain 13 (Fujita et al. 2011), and 
Bifidobacterium bifidum JCM1254 (Shimada et al. 2015) 
have been characterized.
hNAGLU is a lysosomal enzyme that catalyzes the 
hydrolysis of the terminal α1–4-linked N-acetylglu-
cosamine (GlcNAc) at the non-reducing end of heparan 
sulfate (HS) (Birrane et al. 2019; Valstar et al. 2010). HS 
molecules are long unbranched negatively charged gly-
cosaminoglycan (GAG) polysaccharides with disaccha-
ride repeating units comprising an amino sugar and a 
uronic acid (Cartmell et  al. 2017; Wang et  al. 2010). Its 
biosynthesis in eukaryotes involves the formation of hep-
arosan, a linear polysaccharide of a disaccharide repeat-
ing unit of –4GlcNAcα1–4GlcAβ1–, by extending from 
a tetrasaccharide core on proteoglycans followed by 
post-glycosylational modifications (Yu and Chen 2007) 
including GlcNAc N-deacetylation and N-sulfation, GlcA 
C5-epimeration, GlcA/IdoA 2–O–sulfation, glucosamine 
6–O–sulfation and 3–O–sulfation (Esko and Lindahl 
2001). Deficiency of hNAGLU causes a lysosomal storage 
disorder (LSD) (Platt 2018) called mucopolysaccharidosis 
type IIIB (MPS IIIB) or Sanfilippo syndrome B (Sanfili-
ppo type B; MIM 252920) (Yogalingam and Hopwood 
2001; Yogalingam et al. 2000). More than 150 MPS IIIB-
causing mutations in the human NAGLU gene have been 
identified (Andrade et al. 2015). The crystal structure of 
the apo form of a recombinant human NAGLU (rhNA-
GLU, PDB ID: 4XWH) expressing high-mannose type 
N-glycans was reported recently (Birrane et al. 2019).
On the other hand, hNAGLU homologue from 
Clostridium perfringens ATCC 13124 (CpGH89) shares 
28.2% identity with hNAGLU. Its crystal structures 
with or without β-GlcNAc and the crystal structure of 
its E483Q and E601Q double mutant in complex with 
GlcNAcα1–4Gal disaccharide have also been deter-
mined (PDB IDs: 2VCC, 2VCA, and 4A4A) (Ficko-Blean 
and Boraston 2012; Ficko-Blean et  al. 2008). However, 
although also an α-N-acetylglucosaminidase, CpGH89 
was reported to recognize terminal GlcNAcα1–4Gal 
motif in synthetic oligosaccharides and class III mucin 
glycans (Fujita et  al. 2011), which is different from the 
GlcNAcα1–4GlcA and/or GlcNAcα1–4IdoA compo-
nent in the substrates that is recognized by hNAGLU 
(Ficko-Blean and Boraston 2012). A similarly substrate 
specificity of the α-N-acetylglucosaminidase from Bifi-
dobacterium bifidum JCM1254 (BfAgnB) in recognizing 
GlcNAcα1–4Gal-containing oligosaccharides and class 
III mucin glycans was also reported (Shimada et al. 2015).
To look for a bacterial homologue of hNAGLU which 
can catalyze the cleavage of the terminal α-linked Glc-
NAc in heparosan oligosaccharides efficiently, in addition 
to testing the activity of CpGH89 and its loop-truncated 
mutant, we cloned and examined the activities of three 
other GH89 enzymes including Bf0576 from Bacteroides 
fragilis as well as Bt0438 and Bt3590 from Bacteroides 
thetaiotaomicron. Among these, Bt3590 was shown to 
be a highly active α-N-acetylglucosaminidase that can 
catalyze the hydrolysis of terminal GlcNAc from the non-
reducing end of heparosan oligosaccharides with varied 
lengths. It is a promising candidate that can be used for 
chemoenzymatic sequencing of heparin/HS oligosaccha-
rides (Merry et  al. 1999; Turnbull 2001; Turnbull et  al. 
1999).
Materials and methods
Bacterial strains, plasmids, and materials
Escherichia coli DH5α chemically competent cells were 
from Invitrogen (Carlsbad, CA). Genomic DNAs of 
Bacteroides fragilis NCTC 9343 (ATCC#25285), Bac-
teroides thetaiotaomicron VPI-5482 (ATCC#2914D-5), 
and Clostridium perfringens (ATCC#13124) were from 
American Type Culture Collection (ATCC, Manassas, 
VA, USA). Expression vector pET15b was from Novagen 
(EMD Biosciences Inc., Madison, WI, USA). Bio-Scale 
Mini Nuvia IMAC Cartridge and Bio-Scale™ Mini Bio-
Gel® P-6 Desalting Cartridge were from Bio-Rad (Hercu-
les, CA, USA).  AccuPrep® PCR/Gel purification kit was 
from BIONEER Corporation. GeneJET plasmid spin kit, 
1  kb DNA ladder, pre-stained protein ladder and Fast-
Digest BamHI and XhoI restriction enzymes were from 
Fisher Scientific (Tustin, CA, USA).  Phusion® HF DNA 
polymerase,  Q5® site-directed mutagenesis kit,  and T4 
DNA ligase were from New England Biolabs Inc. (Bev-
erly, MA, USA). 4-Methylumbelliferyl 2-acetamido-2-
deoxy-α-D-glucopyranoside (GlcNAcαMU, 1) was from 
Toronto Research Chemicals (North York, Canada) and 
α-GlcNAc-terminated heparosan oligosaccharides 2–6 
were synthesized previously using an efficient chemoen-
zymatic method (Na et al. 2020).
Cloning of full‑length and truncated 
α‑N‑acetylglucosaminidases from B. fragilis, B. 
thetaiotaomicron, and C. perfringens
The genes encoding the full-length Bf0576 from B. fra-
gilis, Bt0438 and Bt3590 from B. thetaiotaomicron, and 
CpGH89 from C. perfringens were amplified by poly-
merase chain reactions (PCRs) from the corresponding 
genomic DNAs. Genes for truncated proteins ∆17Bf0576 
(residues 18–718), ∆24Bt0438 (residues 25–730), and 
∆22Bt3590 (residues 23–732) were amplified from 
the corresponding plasmids containing the full-length 
genes (see below for cloning) by PCRs. DNA sequence 
encoding loop (residues 680–686)-truncated CpGH89 
(tCpGH89) was amplified from the plasmid containing 
the full-length CpGH89 (see below for cloning) using Q5 
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kit. The corresponding primers used are listed in Table 1. 
PCRs were performed in a 50 μL reaction mixture con-
taining 20 ng of genomic DNA or 4 ng of plasmid as the 
template DNA, 1 μM each of forward and reverse prim-
ers, 5 μL of 10 ×  Phusion® HF buffer, 1 mM dNTP mix-
ture, and 5 units (1 μL) of  Phusion® HF DNA polymerase. 
The reaction mixtures were subjected to 35 cycles of 
amplifications with an annealing temperature of 55  °C 
for Bf0576, Bt0438 and Bt3590, 62 °C for CpGH89, 65 °C 
for tCpGH89. For cloning the full-length genes and the 
genes encoding the N-terminal truncated recombinant 
proteins, the resulting PCR products were digested with 
the corresponding restriction enzymes introduced in the 
primers, purified, and ligated with predigested pET15b 
vector. For cloning tCpGH89, the resulting PCR prod-
ucts were purified, and ligated with KLD Enzyme Mix 
included in the  Q5® Site-Directed Mutagenesis Kit. The 
ligated product was transformed into chemically compe-
tent E. coli DH5α cells. Positive plasmids were sequenced 
and subsequently transformed into homemade BL21 
(DE3) chemically competent cells. Selected clones were 
grown for protein expression.
Protein expression, purification, and quantification
The plasmid-bearing E. coli cells were cultured in 1 L 
Luria–Bertani (LB) rich medium (10  g   L−1 tryptone, 
5 g   L−1 yeast extract, and 10 g   L−1 NaCl) supplemented 
with 100 μg  mL−1 ampicillin at 37 °C with shaking. Gen-
erally, overexpression of the target protein was achieved 
by inducing the E. coli culture with 0.1 mM of isopropyl-
1-thio-β-D-galactopyranoside (IPTG) at  OD600  nm  = 
0.8–1.0 and incubating at 20  °C for 20  h with vigorous 
shaking at 250  rpm in a C25KC incubator shaker (New 
Brunswick Scientific, Edison, NJ). Cells were collected by 
centrifugation at 5000×g, 4  °C for 30 min. The cell pre-
cipitation was resuspended in Tris–HCl buffer (100 mM, 
pH 8.0), and then lysed by homogenizer. Cell debris 
was removed by centrifugation at 8000×g and 4  °C for 
30 min, and the enzymes were purified from the super-
natant by Bio-Scale Mini Nuvia IMAC Cartridge follow-
ing the manufacturer’s instructions. Eluted fractions were 
pooled and loaded onto Bio-Scale™ Mini Bio-Gel® P-6 
Desalting Cartridge to remove imidazole and then redis-
solved in  Na2HPO4–NaH2PO4 buffer (0.1 M, pH 6.5). The 
expression of the recombinant proteins was examined 
by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) 
performed in 12% Tris-glycine gels, and the protein con-
centration was determined by NanoDrop Lite spectro-
photometer from Fisher Scientific (Tustin, CA, USA).
Enzyme assays of α‑N‑acetylglucosaminidases using 
GlcNAcαMU (1) as the substrate
Enzymatic assays (20  μL total reaction volume) were 
performed in duplicate in  Na2HPO4–NaH2PO4 buffer 
(0.1 M, pH 6.5) containing GlcNAcαMU (1, 1 mM). An 
enzyme selected from Δ17Bf0576 (0.49 μM), Δ24Bt0438 
(0.048 μM), Δ22Bt3590 (0.012 μM), CpGH89 (0.38 μM), 
or tCpGH89 (0.38  μM) was added and the reactions 
were allowed to proceed at 37 °C for 20 min or 20 h and 
stopped by adding 40 μL methanol. Samples were centri-
fuged and the supernatants were analyzed at 315 nm by 
an Agilent ultra-high performance liquid chromatogra-
phy (UHPLC) system equipped with a membrane on-line 
degasser, a temperature control unit (set at 30 °C), and a 
diode array detector using EclipsePlusC18 RRHD column 
(2.1 × 50 mm I.D., 1.8 μm particle size; Agilent). Mobile 
Table 1 Primers used for cloning full‑length and truncated bacterial α‑N‑acetylglucosaminidases
a Restriction sites are italicized and underlined
Primers Oligonucleotidesa
CpGH89 Forward 5′TTG GCT CTC GAG GGT GTT GAA ATT ACG GAA GGG GTT ACT GTA ACTGC3′
Reverse 5′AGC CAA GGA TCC TTA TGA TTC ATT TTC ACC TAA TAT TTT ATC CAT ATT AGT TAC TGA 
ATA ACT TTC CAT GGC 3′
tCpGH89 Forward 5′CAT TCA AAA ATA GTT TAT GAT AAG AGT GAA TTT GAA AAA GCT ATT GAA ATA TTT GC3′
Reverse 5′TAT TCC AAA GCC TGG TCT TGC ATT TAT AAT AGA CTC AGC3′
Bf0576 Forward 5′GTG TGT CTC GAG ATG AAT CGT AAA TCA ATA CT3′
∆17Bf0576 Forward 5′GTG TGT CTC GAG GCA ATG GCT TCT CCG GTA AC3′
Bf0576 Reverse 5′GTG TGT GGA TCC TTA TTC AAC CGC TTG CAT CA3′
Bt0438 Forward 5′GTG TGT CTC GAG ATG AAC AGA CAA TAC TTC TA3′
∆24Bt0438 Forward 5′GTG TGT CTC GAG AGT AAC CCA GTA TTA GAA CA3′
Bt0438 Reverse 5′GTG TGT GGA TCC TTA ATA AAA ATA TTG CAT ATATT3′
Bt3590 Forward 5′GTG TGT CTC GAG ATG AAT CAT AAA TAC CTA TA3′
∆22Bt3590 Forward 5′GTG TGT CTC GAG ACA GGC CCT CCT GTA TTA AA3′
Bt3590 Reverse 5′GTG TGT GGA TCC TTA TTG TGC TTT GGT AAA GT3′
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phase A was 0.1% trifluoroacetic acid (TFA) in water, and 
mobile phase B was acetonitrile. The system was pre-
equilibrated with a running mobile phase composed of 
mobile phase A and mobile phase B (95/5, v/v) at a flow 
rate of 0.25 mL/min. After injection of the sample, com-
pound separation was carried out with two-phase gradi-
ent elution steps (starting at 95% A  +  5% B at 0 min to 
50% A  +  50% B at 4 min, then back to 95% A  +  5% B at 
5 min with the run stopped at 5.1 min).
Enzyme assays of α‑N‑acetylglucosaminidases using 
GlcNAcα1–4GlcAβProNHFmoc (2) as the substrate
Enzymatic assays (20 μL total reaction volume) were per-
formed in duplicate in  Na2HPO4–NaH2PO4 buffer (0.1 M, 
pH 6.5) containing GlcNAcα1–4GlcAβProNHFmoc (2, 
1 mM). An enzyme selected from Δ17Bf0576 (0.15 mM), 
Δ24Bt0438 (0.036  mM), Δ22Bt3590 (0.003  mM), 
CpGH89 (0.11 mM), or tCpGH89 (0.11 mM) was added 
and the reactions were allowed to proceed at 37 °C for 1 h 
or 20 h and stopped by adding 40 μL methanol. Samples 
were centrifuged and the supernatants were analyzed 
at 254  nm by a Shimadzu LC-2010A high-performance 
liquid chromatography (HPLC) system equipped with a 
membrane on-line degasser, a temperature control unit 
(set at 30 °C), and a diode array detector using  XBridge® 
BEH Amide column (4.6 × 250  mm I.D., 5  μm particle 
size, Waters) protected with a C18 guard column car-
tridge. Mobile phase A was 0.1% formic acid in water, 
and mobile phase B was acetonitrile. The system was 
pre-equilibrated with running mobile phase composed 
of mobile phase A and mobile phase B (20/80, v/v) at a 
flow rate of 0.8  mL/min. After injection of the sample, 
compound separation was carried out in a four-phase 
procedure with an isocratic condition of 20% A  +  80% 
B during 0–5 min, a gradient to 45% A  +  55% B during 
5.0–5.5 min, a gradient back to 20% A  +  80% B during 
5.5–6.0 min, followed by a 2 min-isocratic condition until 
the run was stopped at 8 min.
pH profile of Δ22Bt3590
Enzymatic assays (20  μL total reaction volume) were 
performed in duplicate at 37  °C for 20  min in a buffer 
(100  mM) with a pH in the range of 3.0–10.0, disac-
charide 2 (1  mM), and Δ22Bt3590 (0.51  μM). Buff-
ers used were: citric acid-sodium citrate, pH 3.0–6.5; 
 Na2HPO4-citric acid, pH 7.0–7.5; Tris–HCl, pH 8.0–
8.5; and glycine–NaOH, pH 9.0–10.0. Reactions were 
stopped by adding 40 μL methanol. Samples were centri-
fuged, and then analyzed by HPLC as described above.
Temperature profile assays for Δ22Bt3590
Enzymatic assays (20 μL total reaction volume) were per-
formed in duplicate in citric acid-sodium citrate buffer 
(0.1  M, pH 5.0) containing disaccharide 2 (1  mM) and 
Δ22Bt3590 (0.51  μM) at different temperatures: 10, 15, 
20, 25, 30, 35, 37, 40, 45, 50, 55, and 60 °C. Reactions were 
allowed to proceed for 15  min and stopped by adding 
40 μL methanol. Samples were centrifuged, and then ana-
lyzed by HPLC as described above.
Thermostability assays for Δ22Bt3590
Δ22Bt3590 dissolved in citric acid-sodium citrate buffer 
(0.1  M, pH 5.0) was incubated at 25, 30, and 37  °C for 
1  h, 4  h, 8  h, and 24  h, respectively. After incubation, 
enzymatic assays (20  μL total reaction volume) were 
performed in duplicate at 37  °C in a mixture contain-
ing disaccharide 2 (1  mM) and incubated Δ22Bt3590 
(0.35 μM). Reactions were allowed to proceed for 20 min 
and stopped by adding 40 μL methanol to each reaction 
mixture. Samples were centrifuged, and then analyzed by 
HPLC as described above.
Effects of divalent metal cations, EDTA, and a reducing 
reagent DTT on the activity of Δ22Bt3590
Enzymatic assays were carried out in duplicate at 37  °C 
for 20 min in a total volume of 20 μL in citric acid-sodium 
citrate buffer (0.1  M, pH 5.0) containing disaccharide 
2 (1  mM), Δ22Bt3590 (0.39  μM), and 10  mM of  CaCl2, 
 CuSO4,  MgCl2,  MnCl2,  NiSO4,  ZnCl2, ethylenediamine-
tetraacetic acid (EDTA), or dithiothreitol (DTT). Reac-
tions without metal ions, EDTA, or DTT were used as 
controls. The reactions were quenched by adding 40 μL 
methanol. Samples were centrifuged, and then analyzed 
by HPLC as described above.
Kinetic studies of Δ22Bt3590
To obtain apparent kinetic parameters with GlcNAcαMU 
(1) as the substrate, Δ22Bt3590 (containing 0.001  μM) 
was incubated with various concentrations (0.005, 
0.0066, 0.008, 0.01, 0.0125, 0.02, 0.04, 0.1 and 0.2 mM) of 
GlcNAcαMU (1) in duplicate at 30  °C for 10  min (con-
version was controlled to below 25%) in a total volume of 
40 μL in citric acid-sodium citrate buffer (0.1 M, pH 5.0). 
The reactions were quenched by adding 40 μL methanol 
followed by incubation in an ice bath. Samples were cen-
trifuged and analyzed by UHPLC as described above.
To obtain apparent kinetic parameters with 
GlcNAcα1–4GlcAβProNHFmoc (2) as the substrate, 
Δ22Bt3590 (0.086 μM) was incubated with various con-
centrations (0.05, 0.1, 0.2, 0.4, 0.8, 1.0, 3.0, 5.0, 8.0 and 
10.0  mM) of GlcNAcα1–4GlcAβProNHFmoc (2) in 
duplicate at 30 °C for 10 min in a total volume of 20 μL 
in citric acid-sodium citrate buffer (0.1 M, pH 5.0). The 
reactions were quenched by adding 40  μL methanol. 
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Samples were centrifuged and analyzed by HPLC as 
described above.
The apparent kinetic parameters were obtained by fit-
ting the experimental data (the average values of dupli-
cate assay results) into the Michaelis–Menten equation 
using Grafit 5.0.
Substrate specificity studies of Δ22Bt3590
All reactions were carried out in duplicate at 30  °C or 
37 °C in citric acid-sodium citrate buffer (0.1 M, pH 5.0) 
containing GlcNAcαMU (1) or one of the heparosan 
oligosaccharides GlcNAcα1–4GlcAβ1–(4GlcNAcα1–
4GlcAβ1-)nProNHFmoc (n  =  0–4) (2–6) (1  mM). 
Reactions at 37  °C used 33  μg   mL−1 Δ22Bt3590 and 
aliquots of samples were taken at 20 min, 4 h, and 24 h 
and stopped by adding 40  μL methanol. Reactions at 
30 °C used 29 μg  mL−1 Δ22Bt3590 for 1 h reactions and 
217  μg   mL−1 Δ22Bt3590 for 24  h reactions. Reactions 
were stopped by adding 40 μL methanol, centrifuged, and 
the supernatants were subjected to UHPLC (for reactions 
using GlcNAcαMU 1 as the substrate) or HPLC (for reac-
tions using a heparosan disaccharide 2 as the substrate) 
methods as described above. For samples using a hepa-
rosan oligosaccharide selected from 3–6 as the substrate, 
the UHPLC system is used with an AdvanceBioGlycan 
column (1.8  μm particle, 2.1 × 150  mm, Agilent Tech-
nologies, CA) and monitored at 254 nm. Mobile phase A 
was 0.1% trifluoroacetic acid (TFA) in water, and mobile 
phase B was acetonitrile. The system was pre-equili-
brated with a running mobile phase composed of mobile 
phase A and mobile phase B (10/90, v/v) at a flow rate of 
0.5  mL/min. After injection of the sample, compound 
separation was carried out in a three-phase procedure 
with a gradient starting from 10% A  +  90% B at 0 min 
to 30% A  +  70% B at 9 min followed by another gradient 
back to 10% A  +  90% B for the duration of 9–9.5 min, 
then an isocratic duration till the run was stopped at 
12.5 min.
Results
Cloning and expression of bacterial CAZy GH89 
α‑N‑acetylglucosaminidases
Protein structure-based alignment using UCSF Chi-
mera (Pettersen et al. 2004) and structural overlay using 
PyMOL (Yuan et al. 2016) of CpGH89 (GenBank acces-
sion number ABG84150.1) and hNAGLU reveal an extra 
loop in CpGH89 (residues 680–686) containing a trypto-
phan (W685) residue which was suggested to be impor-
tant for the recognition of the GlcNAcα1–4Gal motif 
of its substrate (Fig.  1; Ficko-Blean and Boraston 2012). 
This loop was hypothesized to restrict the type of the 
substrate that can enter the binding pocket and cause 
the high substrate selectivity of CpGH89, preventing the 
binding of heparan sulfate-type substrate that contain-
ing a terminal GlcNAc α-linked to a β-D-glucuronic acid 
or α-L-iduronic acid (Birrane et  al. 2019; Ficko-Blean 
and Boraston 2012). Therefore, a truncated CpGH89 
(tCpGH89) with this extra loop deleted was designed and 
cloned.
To identify potential bacterial hNAGLU homologues 
that can efficiently use HS as the substrate, protein 
sequence of hNAGLU (GenBank Accession Number 
AEE60931.1) was used to search for candidates in gut 
microbes that are known for their capability of using 
Fig. 1 Structural alignment of hNAGLU (PDB ID: 4XWH, golden) and CpGH89 (PDB ID: 2VCC, cyan) in a cartoon (A) or a surface‑filling (B) 
representation. An extra loop in CpGH89 (residues 680–686) containing W685, the key residue for the recognition of GlcNAcα1–4Gal motif in 
CpGH89 (Birrane et al. 2019; Ficko‑Blean and Boraston 2012), was shown in red in a cartoon presentation. The figures were generated with PyMOL
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host HS as the major source of nutrients (Cartmell et al. 
2017; Martens et al. 2008), Bf0576 from B. fragilis (Gen-
Bank Accession Number CAH06355.1) as well as Bt0438 
(GenBank Accession Number AAO75545.1) and Bt3590 
from B. thetaiotaomicron (GenBank Accession Num-
ber AAO78695.1) were identified. Protein sequence 
alignment of hNAGLU, CpGH89, Bf0576, Bt0438, and 
Bt3590 using the online server Clustal Omega (https:// 
www. ebi. ac. uk/ Tools/ msa/ clust alo/) showed that Bf0576, 
Bt0438, and Bt3590 share 34.6%, 32.8%, and 34.7% pro-
tein sequence identity with hNAGLU and 37.4%, 28.7%, 
and 30% sequence identity with CpGH89, respectively. 
The models of Bf0576, Bt0438, and Bt3590 generated 
by online server SWISS-MODEL (https:// swiss model. 
expasy. org/) were used for further structure-based 
sequence alignment with hNAGLU (PDB ID: 4XWH) 
and CpGH89 (PDB ID: 2VCC) using UCSF Chimera 
(Pettersen et  al. 2004). The Trp-containing extra loop 
presented in CpGH89 could also be found in Bf0576 
structural model but is absent from the structural models 
of Bt0438 and Bt3590 (Fig. 2).
Recombinant Bf0576, Bt0438, and Bt3590 were 
cloned into pET15b vector as N-His6-tagged proteins 
and expressed in BL21 (DE3). However, no significant 
expression of soluble proteins was observed (data not 
shown). After removing the potential transmembrane 
domain predicted by TMHMM Server v. 2.0 (http:// 
www. cbs. dtu. dk/ servi ces/ TMHMM/) at the N-terminus 
of each enzyme, ∆17Bf0576, ∆24Bt0438, and ∆22Bt3590 
lacking the N-terminal 17, 24, and 22 amino acid residues 
were constructed and overexpressed. Soluble recombi-
nant proteins were readily purified by nickel-nitrilotri-
acetic acid  (Ni2+-NTA) affinity chromatography with 
yields of 170 mg, 9 mg, and 136 mg per liter culture with 
expected molecular weights of about 83  kDa, 86  kDa, 
and 86  kDa for ∆17Bf0576, ∆24Bt0438, and ∆22Bt3590 
(Fig.  3), respectively. Full length CpGH89 and the loop 
(residues 680–686)-truncated tCpGH89 (expected 
molecular weights of 104.8  kDa and 104.1  kDa, respec-
tively) (Fig.  3) were expressed under similar conditions 
with yields of 22 mg and 24 mg per liter, respectively.
Activity assays of bacterial CAZy GH89 
α‑N‑acetylglucosaminidases
The activities of recombinant bacterial α-N-
acetylglucosaminidases were assayed using a com-
mercially available fluorophore-tagged substrate, 
4-methylumbelliferyl α-N-acetylglucosaminide (GlcNAcαMU, 
Fig. 2 A segment of structure‑based protein sequence alignment of α‑N‑acetylglucosaminidases including hNAGLU (GenBank accession no. 
AAB06188.1), CpGH89 (GenBank accession no. ABG84150.1), Bf0576 (GenBank accession no. CAH06355.1), Bt0438 (GenBank Accession No. 
AAO75545.1), and Bt3590 (GenBank Accession No. AAO78695.1). The Trp685‑containing extra loop in CpGH89 structure and the corresponding 
predicted loop in Bf0576 structural model are shown in the red square
His6-∆17Bf0576 His6-∆24Bt0438 His6-∆22Bt3590 His6-CpGH89 His6-tCpGH89




Fig. 3 SDS‑PAGE analysis of the expression and purification of recombinant bacterial α‑N‑acetylglucosaminidases including  His6‑CpGH89, and 
loop‑deletion CpGH89  (His6‑tCpGH89),  His6‑∆17Bf0576,  His6‑∆24Bt0438,  His6‑∆22Bt3590. Lanes: M, Thermo Scientific
™ PageRuler™ Plus Prestained 
Protein Ladder (10–250 kDa) for  His6‑∆22Bt3590 samples and Thermo Scientific
™ PageRuler™ Prestained Protein Ladder (10–180 kDa) for other 
samples. The size of the marker with an asterisk on the left is 100 kDa and the size of the marker with a diamond on the left is 75 kDa); BI, whole cell 
extract before induction; AI, whole cell extract after induction; L, lysate after induction; P,  Ni2+‑NTA column purified protein
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1) (Fig. 4), in a quantitative ultra-high performance liquid chro-
matography (UHPLC) assay with a diode array detector. As 
shown in Table 2, all recombinant α-N-acetylglucosaminidases 
tested were able to catalyze the cleavage of GlcNAcαMU at 
pH 6.5, with the highest efficiency observed for ∆22Bt3590, 
followed by ∆24Bt0438 with a medium relative catalytic effi-
ciency. CpGH89, tCpGH89, and ∆17Bf0576 had similar rela-
tive catalytic efficiencies with 24.9–25.5% yields in 20  min 
when 0.38  μM (for CpGH89 or tCpGH89) or 0.49  μM (for 
∆17Bf0576) of enzyme was used. In comparison, ∆24Bt0438 
had a higher yield of 36.6 ± 1.8% in 20 min when it was used 
at an eight–ten-fold lower enzyme concentration (0.048 μM). 
∆22Bt3590 had the highest efficiency with a yield of 38.7 ± 0.3% 
when 0.012 μM of enzyme (32–41-fold less) was used. All reac-
tions went to completion when the reaction time was extended 
to 20 h.
Taking advantage of a previously synthesized fluo-
rophore-labeled heparosan disaccharide GlcNAcα1-
4GlcAβProNHFmoc (2) (Na et al. 2020), the activities of 
the recombinant enzymes in catalyzing the cleavage of 
the terminal α1–4-linked GlcNAc were assayed at pH 6.5. 
As shown in Table  3, although all enzymes were active 
and more than 91% of the substrate could be cleaved 
in 20  h, the concentrations of CpGH89 (0.11  mM), 
tCpGH89 (0.11  mM), and ∆17Bf0576 (0.15  mM) used 
were extremely high. When ∆24Bt0438 was used at 
0.036 mM which was also a relatively high concentration, 
low yields of 12.2 ± 0.8% were achieved. In comparison, 
∆22Bt3590 was able to catalyze the cleavage quite effi-
ciently. When it was used at 0.003 mM, a concentration 
that was 12-fold lower than that of the ∆24Bt0438 and 
37–50-fold lower than others, yields of 42.9 ± 1.2% were 
achieved, which were about 3.5-fold higher than that 
of the ∆24Bt0438. These results indicated that among 
the five recombinant enzymes, ∆22Bt3590 was the 
most efficient in catalyzing the cleavage of the terminal 
α1–4-linked GlcNAc from the heparosan disaccharide 
GlcNAcα1–4GlcAβProNHFmoc (2) at pH 6.5.
pH profile of ∆22Bt3590 activity
Using GlcNAcα1–4GlcAβProNHFmoc (2) as the sub-
strate, ∆22Bt3590 was further characterized for its pH 
profile. It preferred an acidic pH and the optimal activity 
was at pH 5.0 in sodium citrate buffer (Fig. 5A). Its activ-
ity decreased dramatically when the pH fell below 4.0 or 
rose above 6.0.
Effect of divalent metal cations, 
ethylenediaminetetraacetic acid (EDTA), and dithiothreitol 
(DTT) on the activity of ∆22Bt3590
The effects of various metal ions, the chelating reagent 
EDTA, and the reducing reagent DTT on the enzyme 
activity of ∆22Bt3590 were examined at pH 5.0. Reac-
tions without metal ions were used as controls. As shown 
in Fig.  5B, a divalent metal cation was not required for 
the catalytic activity of ∆22Bt3590 as 10  mM of EDTA 
had no effect. Nevertheless, the presence of 10  mM 
 CuCl2 decreased the reaction yields of ∆22Bt3590 slightly 
and the addition of  MnCl2 or  ZnCl2 almost abolished its 
Fig. 4 Structures of substrates (1–6) used for 
α‑N‑acetylglucosaminidase activity assays
Table 2 Activity comparison of recombinant bacterial 
α‑N‑acetylglucosaminidases in catalyzing the cleavage of 
GlcNAcαMU (1) at pH 6.5 and 37 °C




CpGH89 0.38 25.2 ± 0.4 100
tCpGH89 0.38 24.9 ± 0.4
∆17Bf0576 0.49 25.5 ± 1.5
∆24Bt0438 0.048 36.6 ± 1.8
∆22Bt3590 0.012 38.7 ± 0.3
Table 3 Activity comparison of recombinant bacterial α‑N‑
acetylglucosaminidases in catalyzing the cleavage of GlcNAcα1–
4GlcAβProNHFmoc (2) at pH 6.5 and 37 °C




CpGH89 0.11 13.9 ± 0.7 96.0 ± 0.4
tCpGH89 0.11 23.7 ± 1.9 100
∆17Bf0576 0.15 66.9 ± 0.6 100
∆24Bt0438 0.036 12.2 ± 0.8 91.4 ± 0.6
∆22Bt3590 0.003 42.9 ± 1.2 97.0 ± 0.4
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activity completely. On the other hand, no significant 
effect in the activity of ∆22Bt3590 was observed for the 
reducing reagent DTT.
Temperature profile studies of ∆22Bt3590
∆22Bt3590 was shown to have optimal activities in 
the temperature range of 35–40  °C (Fig.  6A) and about 
90% of the optimal activity was observed at 45  °C. Its 
activity decreased dramatically when the temperature 
reached 50 °C or higher. About 50% of the optimal activ-
ity was observed at 30 °C and the activity decreased with 
the decrease of the temperature. Minimal activity was 
observed at 10 °C.
Thermostability studies of ∆22Bt3590
Thermostability studies of ∆22Bt3590 by incubating it at 
different temperatures (25  °C, 30  °C, and 37  °C) for dif-
ferent durations (1 h, 4 h, 8 h, and 24 h) in sodium citrate 
buffers (0.1 M, pH 5.0) showed (Fig. 6B) that the enzyme 
retained 89%, 83%, and 52% activities, respectively, after 
incubation at 25  °C, 30  °C, and 37  °C, for 1  h and 77%, 
58%, and 13% activities, respectively, after incubation at 
25  °C, 30  °C, and 37  °C, for 4  h. Incubating ∆22Bt3590 
at 37  °C for 8  h or more almost abolished its activity 
while 71% and 38% activities retained, respectively, after 
incubation at 25 °C and 30 °C for 8 h. Incubation of the 
enzyme at 30 °C for 24 h also abolished its activity while 
49% activity retained even after incubating the enzyme 
for 24 h at 25 °C.
Apparent kinetic parameters of ∆22Bt3590
As shown in Table  4, the KM value of ∆22Bt3590 for 
GlcNAcαMU (1) (4.6 ± 0.4 μM) obtained was much lower 
than those obtained for hNAGLU when GlcNAcαMU 
(0.17–0.33  mM) (Birrane et  al. 2019; Zhao and Neufeld 
2000), GlcNAcαpNP or two other aryl 2-acetamido-2-
deoxy-α-glucosides and UDP-GlcNAc (0.14–0.74  mM) 

































































































Fig. 6 Temperature profiles (A) and thermostability (B) of ∆22Bt3590
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less than that of CpGH89 using GlcNAcαpNP (1.1 mM) 
or 2,4-dinitrophenyl α-N-acetyl-D-glucosaminide 
(GlcNAcαDNP, 0.74  mM) as the substrates (Ficko-
Blean et  al. 2008). Compared to GlcNAcαMU (1), 
GlcNAcα1–4GlcAβProNHFmoc (2) was a less preferred 
substrate for ∆22Bt3590 which showed a much higher 
KM value (2.19 ± 0.16  mM) than that for GlcNAcαMU 
(1) (KM = 4.6 ± 0.4  μM), which led to about 490-fold 
lower kcat/KM value (1.63   s−1   mM−1) when GlcNAcα1–
4GlcAβProNHFmoc (2) was used as the substrate for 
∆22Bt3590.
Substrate specificity studies of ∆22Bt3590
Using GlcNAcαMU (1) and synthetic α-GlcNAc-
terminated fluorophore-tagged heparosan oligosac-
charides of varied lengths (2–6, Fig.  4) (Na et  al. 2020) 
as substrates, substrate specificity studies of ∆22Bt3590 
at 37  °C showed that heparosan oligosaccharides with 
longer lengths were poorer substrates than heparosan 
disaccharide 2 (Fig.  7A) and the yield of the catalytic 
reactions, in general, decreased with the increase of the 
substrate length. In agreement with the thermostabil-
ity study results, ∆22Bt3590 lost most of its activity after 
4 h-incubation at 37 °C as no further yield improvement 
was observed for the reactions with 24 h incubation com-
pared to those with 4 h incubation time.
When the reaction temperature was decreased to 30 °C 
where ∆22Bt3590 was more stable (Fig. 6), an incubation 
time of 24  h was able to improve the reaction yields to 
reach more than 95% completion for all substrates tested 
(Fig. 7B).
Discussion
Bacteroides thetaiotaomicron is a Gram-negative gut 
symbiotic bacterium which is well known for contain-
ing a large number of glycoside hydrolases and its capa-
bility of using different polysaccharides as nutrients 
(Cartmell et  al. 2017; Xu and Gordon 2003). The com-
plete 6.26-Mb genome sequence of B. thetaiotaomicron 
strain VPI-5482 (ATCC#29148) (Comstock and Coyne 
2003; Xu et al. 2003) was predicted by PULDB database 
(http:// www. cazy. org/ PULDB/) (Terrapon et  al. 2015, 
2018) to encode more than 100 glycoside hydrolases 
responsible for breaking down a wide variety of poly-
saccharides. Nevertheless, among enzymes in B. the-
taiotaomicron that are predicted to be responsible for 
glycosaminoglycan degradation (Ahn et al. 1998; Hooper 
et  al. 2002; Ndeh et  al. 2018, 2020), only polysaccha-
ride lyases (PLs) and a GH88 ∆4,5-unsaturated uronyl 
hydrolase (Bt4658) have been biochemically character-
ized for using heparin and HS as high-priority nutrient 
sources by B. thetaiotaomicron (Cartmell et  al. 2017; 
Dong et al. 2012; Han et al. 2009; Luo et al. 2007; Ulaga-
nathan et al. 2017; Xu et al. 2003). Although B. thetaio-
taomicron hNAGLU homologues in CAZy GH89 family 
were predicted to be α-N-acetylglucosaminidases that 
are involved in HS degradation based on deduced pro-
tein sequences from the B. thetaiotaomicron genomic 
sequence (Comstock and Coyne 2003; Martens et  al. 
Table 4 Apparent kinetic parameters of ∆22Bt3590
Substrates GlcNAcαMU (1) GlcNAcα1–
4GlcAβProNHFmoc 
(2)
KM (mM) (4.6 ± 0.4) ×  10−3 2.19 ± 0.16
kcat  (s
−1) 3.68 ± 0.07 3.57 ± 0.09
kcat/KM  (s












































Fig. 7 Substrate specificities of ∆22Bt3590 at 37 °C (A) or 30 °C (B) using GlcNAcαMU (1) and synthetic α‑GlcNAc‑terminated fluorescent‑tagged 
heparosan oligosaccharides of varied lengths (2–6, Fig. 4) as potential substrates. Reaction times vary from 20 min (white columns), 1 h (patten filled 
columns), 4 h (black columns), to 24 h (gray columns)
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2008), none have been characterized so far. Here we pro-
vide evidence that Bt0438 and Bt3590 from B. thetaio-
taomicron VPI-5482 (ATCC#29148) as well as Bf0576 
from of Bacteroides fragilis NCTC 9343 (ATCC#25285) 
are α-N-acetylglucosaminidases. While their full-length 
proteins did not expressed well in E. coli BL21(DE3) 
in a pET15b vector, N-terminal truncation led to the 
successful expression of the recombinant proteins 
∆17Bf0576 (170 mg/L culture), ∆24Bt0438 (9 mg/L cul-
ture), and ∆22Bt3590 (136 mg/L culture) as soluble and 
active enzymes. Among these three, ∆22Bt3590 was the 
most efficient in catalyzing the cleavage of the terminal 
α-GlcNAc from commercially available GlcNAcαMU 
(1) at pH 6.5. ∆22Bt3590 was also shown to be able to 
use synthetic heparosan oligosaccharides (2–6) with an 
α-GlcNAc at the non-reducing end as the substrates.
A W638-containing loop in CpGH89 (Ficko-Blean 
et al. 2008; Yogalingam et al. 2000) that is absent in hNA-
GLU (Birrane et  al. 2019) was suggested to be critical 
for the recognition of the specific GlcNAcα1–4GalβOR-
type substrate by CpGH89. The presence of this loop 
introduces an extra tryptophan residue (Trp685) in the 
substrate-binding pocket of CpGH89 which is absent in 
hNAGLU (Fig. 8). Such a loop is also present in the struc-
tural model of Bf0576 but is absent from the structural 
models of Bt0438 and Bt3590. The loop-truncated ver-
sion of CpGH89 (tCpGH89) showed a twofold higher 
activity in using GlcNAcα1–4GlcAβProNHFmoc (2) as 
the substrate compared to CpGH89.
While ∆22Bt3590 was the most reactive at 37  °C and 
pH 5.0 (Fig. 6A), it lost most of its activity after 4 h-incu-
bation under this condition (Fig.  6B). In comparison, 
while at 30  °C ∆22Bt3590 was performing at 50% of its 
optimal activity (Fig. 6A), it was more stable and retained 
38% activity even after 8 h-incubation under this condi-
tion (Fig. 6B). Indeed, ∆22Bt3590 was shown to be able 
to catalyze almost the complete cleavage of the termi-
nal α-GlcNAc from heparosan disaccharide (2), tetra-
saccharide (3), hexasaccharide (4), octasaccharide (5), 
and decasaccharide (6) at 30 °C within 24 h (Fig. 6B). In 
comparison, the cleavage of the terminal α-GlcNAc from 
heparosan oligosaccharides that was tetrasaccharide 
Fig. 8 Structural overlay of the active sites of hNAGLU (PDB ID:4XWH, golden), CpGH89 (cyan) in complex with GlcNAc (green) (PDB ID: 2VCA), and 
Bt3590 model (magenta). The GlcNAc ligand (green) and the key residues in the active sites (labeled in black for hNAGLU, cyan for CpGH89, and 
magenta for Bt3590) are shown in stick representations. The figure was generated with UCSF Chimera (Pettersen et al. 2004)
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or larger (3–6) at 37 °C was incomplete even with up to 
24 h-incubation time (Fig. 6A).
Unlike hNAGLU which has not been successfully 
expressed in E. coli, N-His6-tagged ∆22Bt3590 was 
readily expressed in E. coli as an active and soluble pro-
tein. About 136 mg protein was able to be purified from 
one liter of E. coli cell culture. Biochemical characteri-
zation of ∆22Bt3590 demonstrated that it had a similar 
optimal pH range (pH 4.5–5.0) and overall pH profile 
as hNAGLU (pH 4.2–4.8) (FIGURA 1977). ∆22Bt3590 
could be a useful tool to replace hNAGLU in a strat-
egy combining nitrous acid degradation and highly spe-
cific exolytic lysosomal enzymes for rapid and direct 
sequencing of heparin/HS saccharides (Merry et  al. 
1999; Turnbull 2001; Turnbull et al. 1999).
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